IL251729B - Use of glucocorticoid and mineralocorticoid receptor antagonists to treat fatty liver disease - Google Patents

Use of glucocorticoid and mineralocorticoid receptor antagonists to treat fatty liver disease

Info

Publication number
IL251729B
IL251729B IL251729A IL25172917A IL251729B IL 251729 B IL251729 B IL 251729B IL 251729 A IL251729 A IL 251729A IL 25172917 A IL25172917 A IL 25172917A IL 251729 B IL251729 B IL 251729B
Authority
IL
Israel
Prior art keywords
glucocorticoid
receptor antagonists
liver disease
fatty liver
disease treatment
Prior art date
Application number
IL251729A
Other languages
English (en)
Hebrew (he)
Other versions
IL251729A0 (en
Inventor
Hunt Hazel
K Belanoff Joseph
C Meijer Onno
VAN DEN HEUVEL Jose
Original Assignee
Corcept Therapeutics Inc
Hunt Hazel
K Belanoff Joseph
C Meijer Onno
VAN DEN HEUVEL Jose
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corcept Therapeutics Inc, Hunt Hazel, K Belanoff Joseph, C Meijer Onno, VAN DEN HEUVEL Jose filed Critical Corcept Therapeutics Inc
Publication of IL251729A0 publication Critical patent/IL251729A0/en
Publication of IL251729B publication Critical patent/IL251729B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL251729A 2014-10-15 2017-04-13 Use of glucocorticoid and mineralocorticoid receptor antagonists to treat fatty liver disease IL251729B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462064358P 2014-10-15 2014-10-15
US201462092041P 2014-12-15 2014-12-15
PCT/US2015/055487 WO2016061195A1 (en) 2014-10-15 2015-10-14 Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists

Publications (2)

Publication Number Publication Date
IL251729A0 IL251729A0 (en) 2017-06-29
IL251729B true IL251729B (en) 2020-03-31

Family

ID=55747256

Family Applications (1)

Application Number Title Priority Date Filing Date
IL251729A IL251729B (en) 2014-10-15 2017-04-13 Use of glucocorticoid and mineralocorticoid receptor antagonists to treat fatty liver disease

Country Status (22)

Country Link
US (5) US10238659B2 (enExample)
EP (2) EP4353310A3 (enExample)
JP (1) JP6761410B2 (enExample)
KR (1) KR102435956B1 (enExample)
CN (2) CN111557942B (enExample)
AU (1) AU2015333645B2 (enExample)
BR (1) BR112017007860B1 (enExample)
CA (1) CA2964625C (enExample)
DK (1) DK3206692T3 (enExample)
ES (1) ES2978871T3 (enExample)
FI (1) FI3206692T3 (enExample)
IL (1) IL251729B (enExample)
MX (1) MX2017004943A (enExample)
NZ (1) NZ731060A (enExample)
PH (1) PH12017500710B1 (enExample)
PL (1) PL3206692T3 (enExample)
PT (1) PT3206692T (enExample)
RU (1) RU2718921C2 (enExample)
SG (1) SG11201703024VA (enExample)
UA (1) UA123537C2 (enExample)
WO (1) WO2016061195A1 (enExample)
ZA (1) ZA201702813B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12017500710B1 (en) 2014-10-15 2024-01-17 Corcept Therapeutics Inc Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists
KR102589213B1 (ko) * 2018-06-04 2023-10-12 코어셉트 쎄라퓨틱스 인코포레이티드 피리미딘 사이클로헥세닐 글루코코르티코이드 수용체 조절제
US20220288091A1 (en) 2019-03-18 2022-09-15 Lynnette K. NIEMAN Method for Improving Insulin Sensitivity
BR112022022473A2 (pt) * 2020-05-06 2022-12-13 Corcept Therapeutics Inc Formulações de moduladores de receptor de glucocorticoide ciclo-hexil pirimidina
US11548856B2 (en) 2020-05-06 2023-01-10 Corcept Therapeutics Incorporated Polymorphs of pyrimidine cyclohexyl glucocorticoid receptor modulators
KR102481705B1 (ko) * 2020-08-04 2022-12-27 연세대학교 산학협력단 트리아졸 유도체를 유효성분으로 포함하는 간 섬유증의 예방 또는 치료용 조성물
IL303881A (en) * 2020-12-21 2023-08-01 Corcept Therapeutics Inc Method of preparing pyrimidine cyclohexyl glucocorticoid receptor modulators
EP4333848A4 (en) * 2021-05-05 2025-03-19 Corcept Therapeutics Incorporated Methods for reducing liver fat and treating fatty liver disease
WO2025174745A1 (en) * 2024-02-12 2025-08-21 Corcept Therapeutics Incorporated MIRICORILANT TREATMENT FOR FATTY LIVER DISEASES and its EFFECTS on LIVER FAT CONTENT, FATTY ACIDS, ACYLGLYCEROLS, and SECONDARY BILE ACIDS

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2153546A (en) 1936-07-29 1939-04-11 Universal Draft Gear Attachmen Hand brake actuating mechanism
US4391904A (en) 1979-12-26 1983-07-05 Syva Company Test strip kits in immunoassays and compositions therein
GB0213745D0 (en) * 2002-06-14 2002-07-24 Univ Edinburgh Enzyme
EP1534273A4 (en) 2002-07-18 2007-08-22 Bristol Myers Squibb Co MODULATORS OF THE GLUCOCORTICOID RECEPTOR AND METHOD
AU2006247537B2 (en) 2005-05-18 2011-01-06 Merck Sharp & Dohme Corp. D-homoandrosta-17-yl-carbamate derivatives as selective glucocorticoid receptor ligands
US8389472B2 (en) * 2005-08-19 2013-03-05 Amylin Pharmaceuticals, Llc Exendin-4 to treat nonalcoholic steatohepatitis and nonalcoholic fatty liver disease
KR20080065617A (ko) * 2005-09-19 2008-07-14 존슨 앤드 존슨 파머슈티컬 리서치 앤드 디벨로프먼트 엘엘씨 글루코코티코이드 수용체 발현의 조절
GB0601092D0 (en) * 2006-01-19 2006-03-01 Daniolabs Ltd The Prevention Of Systemic Side-Effects Of Glucocorticoids
EP2032134B1 (en) 2006-05-09 2015-06-24 Genzyme Corporation Methods of treating fatty liver disease comprising inhibiting glucosphingolipid synthesis
US9623021B2 (en) 2007-01-22 2017-04-18 Gtx, Inc. Nuclear receptor binding agents
WO2008127591A2 (en) * 2007-04-13 2008-10-23 Schering Corporation Pyrimidinedione derivatives and use thereof
US8003689B2 (en) 2008-06-20 2011-08-23 Gtx, Inc. Metabolites of selective androgen receptor modulators and methods of use thereof
JP5511942B2 (ja) 2009-04-03 2014-06-04 エフ ホフマン−ラ ロッシュ アクチェン ゲゼルシャフト 組成物及びその使用
EP2685827B1 (en) 2011-03-18 2016-02-03 Corcept Therapeutics, Inc. Pyrimidine cyclohexyl glucocorticoid receptor modulators
PH12017500710B1 (en) 2014-10-15 2024-01-17 Corcept Therapeutics Inc Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists

Also Published As

Publication number Publication date
BR112017007860B1 (pt) 2023-03-07
FI3206692T3 (fi) 2024-05-06
EP4353310A2 (en) 2024-04-17
JP2017531013A (ja) 2017-10-19
PH12017500710B1 (en) 2024-01-17
JP6761410B2 (ja) 2020-09-23
CN111557942A (zh) 2020-08-21
US10238659B2 (en) 2019-03-26
AU2015333645A1 (en) 2017-05-04
RU2017114596A3 (enExample) 2019-05-08
US20210085682A1 (en) 2021-03-25
WO2016061195A1 (en) 2016-04-21
SG11201703024VA (en) 2017-05-30
ES2978871T3 (es) 2024-09-23
CA2964625A1 (en) 2016-04-21
BR112017007860A2 (pt) 2018-01-16
EP3206692A1 (en) 2017-08-23
EP3206692A4 (en) 2018-05-30
RU2017114596A (ru) 2018-11-15
US11590135B2 (en) 2023-02-28
US12226417B2 (en) 2025-02-18
PL3206692T3 (pl) 2024-07-22
PH12017500710A1 (en) 2017-10-09
ZA201702813B (en) 2019-05-29
KR102435956B1 (ko) 2022-08-23
PT3206692T (pt) 2024-04-30
IL251729A0 (en) 2017-06-29
US20190151318A1 (en) 2019-05-23
CN111557942B (zh) 2023-10-03
AU2015333645B2 (en) 2020-01-30
KR20170066646A (ko) 2017-06-14
DK3206692T3 (da) 2024-04-29
UA123537C2 (uk) 2021-04-21
CN107106562B (zh) 2020-08-18
RU2718921C2 (ru) 2020-04-15
EP4353310A3 (en) 2024-06-19
US10881660B2 (en) 2021-01-05
US20250221995A1 (en) 2025-07-10
US20230218621A1 (en) 2023-07-13
MX2017004943A (es) 2017-07-19
CN107106562A (zh) 2017-08-29
NZ731060A (en) 2023-07-28
CA2964625C (en) 2023-03-07
US20160106749A1 (en) 2016-04-21
EP3206692B1 (en) 2024-04-03

Similar Documents

Publication Publication Date Title
ZA201702813B (en) Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists
IL247713A0 (en) Indazole 3-carboxyamides converted at the 5-position, their preparation and their use
SG11201609645YA (en) Device for connecting the structural elements of ribs and reticular structures
AU201710083S (en) Bowl and Covered Bowl
GB201404470D0 (en) Therapeutic methods and materials
AU357565S (en) Mixing bowls
ZA201706671B (en) Process for the preparation of androgen receptor antagonists and intermediates thereof
SG11201608217PA (en) Fatty acid composition and use thereof
IL246489A0 (en) Methods for using anti-steap1 antibodies and immunoconjugates
ZA201703398B (en) Pharmaceutical composition and methods
IL249203A0 (en) Androgen receptor modulators and methods of using them
GB2530559B (en) Mixing bowl
IL265560A (en) Preparations containing a mineralocorticoid receptor antagonist and their uses
PT3113774T (pt) Composições de grapiprant e métodos de utilização das mesmas
IL247828A0 (en) Progesterone compounds
IL246944B (en) A process for the preparation of abiraterone acetate and its intermediates
GB201612052D0 (en) Animal claw shearing apparatuses and methods of using the same
GB201810451D0 (en) Anti-placenta-chondroitin-sulfate chimeric antigen receptor and application thereof
GB201520661D0 (en) Mixing bowl
GB201411741D0 (en) Mixing bowl stand
GB201402210D0 (en) Mixing bowl
GB201419977D0 (en) Dynamic mixer and mixing
GB201402629D0 (en) Improved mixer and associated methods
GB201419559D0 (en) Therapeutic compositions and methods

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed